- Home
- CET vs ADPT Comparison
CET vs ADPT Comparison
Compare CET & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- ADPT
- Stock Information
- Founded
- CET 1929
- ADPT 2009
- Country
- CET United States
- ADPT United States
- Employees
- CET N/A
- ADPT N/A
- Industry
- CET Finance/Investors Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CET Finance
- ADPT Health Care
- Exchange
- CET Nasdaq
- ADPT Nasdaq
- Market Cap
- CET 1.4B
- ADPT 1.4B
- IPO Year
- CET N/A
- ADPT 2019
- Fundamental
- Price
- CET $47.04
- ADPT $10.38
- Analyst Decision
- CET
- ADPT Strong Buy
- Analyst Count
- CET 0
- ADPT 7
- Target Price
- CET N/A
- ADPT $10.57
- AVG Volume (30 Days)
- CET 14.8K
- ADPT 1.3M
- Earning Date
- CET 01-01-0001
- ADPT 07-31-2025
- Dividend Yield
- CET 4.89%
- ADPT N/A
- EPS Growth
- CET 26.33
- ADPT N/A
- EPS
- CET 9.95
- ADPT N/A
- Revenue
- CET $23,698,535.00
- ADPT $189,527,000.00
- Revenue This Year
- CET N/A
- ADPT $24.46
- Revenue Next Year
- CET N/A
- ADPT $20.25
- P/E Ratio
- CET $4.73
- ADPT N/A
- Revenue Growth
- CET 11.75
- ADPT 8.61
- 52 Week Low
- CET $40.24
- ADPT $2.99
- 52 Week High
- CET $49.51
- ADPT $10.87
- Technical
- Relative Strength Index (RSI)
- CET 55.86
- ADPT 62.28
- Support Level
- CET $46.47
- ADPT $9.90
- Resistance Level
- CET $47.68
- ADPT $10.85
- Average True Range (ATR)
- CET 0.51
- ADPT 0.48
- MACD
- CET -0.09
- ADPT -0.02
- Stochastic Oscillator
- CET 60.12
- ADPT 68.39
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).